Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
JHEP Reports : Innovation in Hepatology|March 9, 2026
Prognostic implications of tumour number in intrahepatic cholangiocarcinomaBrandon Lok-Hang Chan, Yan Li, YoungJae Kim, et al.
Alimentary Pharmacology & Therapeutics|September 17, 2019
Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosisKen Liu, Jonggi Choi, An Le, et al.
The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland|August 16, 2017
Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinomaCharing Ching-Ning Chong, Anthony Wing-Hung Chan, John Wong, et al.
Liver Cancer|July 11, 2020
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus StatementsMasatoshi Kudo, Kwang-Hyub Han, Sheng-Long Ye, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinomaHenry Lik-Yuen Chan, Chi-Hang Tse, Frankie Mo, et al.
Cancer Medicine|January 10, 2025
Concomitant Usage of H1-Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient SurvivalYin Leung, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, et al.
Journal of Vascular and Interventional Radiology : JVIR|January 25, 2016
Transarterial Ethanol Ablation for Unresectable Hepatocellular Carcinoma: Analysis of Clinical and Tumor OutcomesSimon Chun Ho Yu, Edwin Pun Hui, Peggy Tang, et al.
Radiology|December 23, 2017
Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional ChemoembolizationSimon Chun Ho Yu, Stephen Lam Chan, Kit Fai Lee, et al.
Liver Cancer|May 12, 2021
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective StudyChanghoon Yoo, Jwa Hoon Kim, Min-Hee Ryu, et al.
Alimentary Pharmacology & Therapeutics|September 6, 2025
Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver CancerDorothy Cheuk-Yan Yiu, Jimmy Che-To Lai, Landon Long Chan, et al.
Pageof 7